Ligand Pharmaceuticals Incorporated
LGND
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.7B
$285.60
▼ -1.43%
P/E
29.91
Mkt Cap
$5.7B
52-Wk Range
$161.82–$326.63
52-Week Range
$161.82 - $326.63
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 72.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Captisol proprietary technology platform enabling superior drug formulations and bioavailability
- Diversified portfolio across multiple therapeutic areas reducing revenue concentration risk
- Strategic licensing partnerships generating recurring royalty revenue streams
- Established commercial infrastructure and regulatory expertise for rapid market access
- Acquisition-focused strategy providing access to innovative technologies and approved products
Bear Case
2 risks
- Average volatility.
- Growth premium of 1.4x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Stable outlook
Strong revenue growth (60% YoY)
Value
Growth premium of 1.4x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+20.1% over 3m
Quality
Excellent
High-growth business (55% revenue growth, 99% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying LGND right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $2.37 vs $1.97 consensus (+20.3% surprise). Revenue of $63.7M vs $61.3M expected (+3.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+20.3%
Revenue trend · last 8Q
—
+52%
+46%
+15%
+123%
+39%
+14%
+34%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$51.8M
$42.8M
$45.3M
$47.6M
$115.5M
$59.7M
$51.7M
$63.7M
Margins · last 8Q
Gross
100.0%
Operating
13.5%
Profit
76.2%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 12, 2026
vs Industry
How LGND stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related